NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

RecruitingPhase 2

Sponsor: Arrowhead Pharmaceuticals

Conditions: Asthma

Interventions: ARO-RAGE, Placebo

Countries: Canada

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
* Established allergy confirmed by positive skin prick test at screening
* Willing and able to perform lung function tests and other study-related procedures
* Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later

Exclusion Criteria:

* Concomitant diagnosis of a clinically important pulmonary disease other than asthma
* Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
* History or current medical condition contraindicating methacholine challenge

Note: Additional inclusion/exclusion criteria may apply per protocol.

Locations (5)

Vancouver, British Columbia, Canada
Calgary, Canada
Edmonton, Canada
Hamilton, Canada
Saskatoon, Canada